Aktienanalyse zu Acurx Pharmaceuticals Inc (ACXP)ACXPAcurx Pharmaceuticals Inc

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Acurx Pharmaceuticals Inc is not a good buy right now due to its current price of $1.44, which is significantly lower than the analyst price target of $10. However, the stock has shown some positive movement with a recent 18.28% increase following FDA news, despite a year-to-date decline of 47.83%. The main risk is the projected net loss of $2.25 million in Q2 2026, which raises concerns about its financial stability.